SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Aegerion Pharmaceuticals, Inc. to Contact Brower Piven Before the March 17, 2014 Lead Plaintiff Deadline -- AEGR

STEVENSON, Md., Jan. 17, 2014 (GLOBE NEWSWIRE) -- Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company") (Nasdaq:AEGR) securities during the period between March 15, 2012 and January 9, 2014, inclusive (the "Class Period").

If you are a shareholder who purchased Aegerion securities during the class period, you may obtain additional information about this lawsuit and your ability to become a lead plaintiff, at no cost to you, by contacting Brower Piven at, by email at, by calling 410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and class action cases of over 60 years.

No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than March 17, 2014 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Company units during the Class Period.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants' failure to disclose that the Company marketed its drugs in violation of the Federal Food Drug and Cosmetic Act, including Juxtapid, and as a result, the Company faced heightened regulatory scrutiny by the Food and Drug Administration and other governmental bodies. According to the complaint, after the Company received a subpoena from the U.S. Department of Justice on January 10, 2014 requesting documents regarding its marketing and sale of Juxtapid, the value of Aegerion shares declined significantly.

If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

CONTACT: Charles J. Piven Brower Piven, A Professional Corporation Stevenson, Maryland 410/415-6616 hoffman@browerpiven.comSource: Brower Piven, A Professional Corporation